CAR T-Cell Therapy: Expert Guidance for Community Practice

Commentary on the evolving therapeutic landscape in peripheral T-cell lymphomas with a focus on EZH1/2 inhibition, from Clinical Care Options (CCO)

Steven M. Horwitz, MD
Program Director Pamela B. Allen, MD Pierluigi Porcu, MD Released: August 8, 2022

Video featuring Jesús Berdeja, MD, and Sagar Lonial, MD, discussing the latest evidence on approved and investigational CAR T-cell therapies for multiple myeloma, from Clinical Care Options (CCO)

Jesús G. Berdeja, MD Sagar Lonial, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 5, 2022 Expired: August 4, 2023

Expert webcast recording of live webinar on selecting therapy and managing toxicities for indolent B-cell lymphomas, from Clinical Care Options (CCO)

Elizabeth Brém, MD
Program Director Christopher R. Flowers, MD, MS
Program Director Pallawi Torka, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 3, 2022 Expired: August 2, 2023

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Othman Al-Sawaf, MD Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: July 29, 2022